Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSI NASDAQ:KROS NASDAQ:RNA NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$13.83+8.0%$21.34$7.78▼$34.10$199.37M1.4244,188 shs34,326 shsKROSKeros Therapeutics$10.09+1.2%$10.75$9.69▼$22.55$199.64M0.97350,335 shs31,934 shsRNAAvidity Biosciences$11.38+1.8%$12.56$11.13▼$16.77$194.67M0.93423,192 shs35,489 shsTCRXTScan Therapeutics$0.77+3.6%$0.96$0.73▼$2.57$50.06M1.04724,852 shs265,910 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-5.06%-3.77%-45.08%-45.94%+14.73%KROSKeros Therapeutics-0.99%-2.35%-8.78%-10.34%-31.15%RNAAvidity Biosciences-2.70%-8.13%-18.10%-12.45%-68.90%TCRXTScan Therapeutics-4.19%-17.57%-24.13%-36.07%-58.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$13.83+8.0%$21.34$7.78▼$34.10$199.37M1.4244,188 shs34,326 shsKROSKeros Therapeutics$10.09+1.2%$10.75$9.69▼$22.55$199.64M0.97350,335 shs31,934 shsRNAAvidity Biosciences$11.38+1.8%$12.56$11.13▼$16.77$194.67M0.93423,192 shs35,489 shsTCRXTScan Therapeutics$0.77+3.6%$0.96$0.73▼$2.57$50.06M1.04724,852 shs265,910 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-5.06%-3.77%-45.08%-45.94%+14.73%KROSKeros Therapeutics-0.99%-2.35%-8.78%-10.34%-31.15%RNAAvidity Biosciences-2.70%-8.13%-18.10%-12.45%-68.90%TCRXTScan Therapeutics-4.19%-17.57%-24.13%-36.07%-58.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 2.33Hold$57.00312.30% UpsideKROSKeros Therapeutics 2.25Hold$20.40102.28% UpsideRNAAvidity Biosciences 2.28Hold$67.60494.02% UpsideTCRXTScan Therapeutics 2.33Hold$6.00681.25% UpsideCurrent Analyst Ratings BreakdownLatest TCRX, GLSI, KROS, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026GLSIGreenwich LifeSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $69.007/17/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$5.006/23/2026TCRXTScan Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/19/2026RNAAvidity Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/18/2026RNAAvidity Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.005/22/2026RNAAvidity Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E-)5/15/2026GLSIGreenwich LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026KROSKeros Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026RNAAvidity Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/1/2026RNAAvidity Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.03 per shareN/AKROSKeros Therapeutics$244.06M0.82$4.54 per share2.22$15.51 per share0.65RNAAvidity Biosciences$36.68M5.31N/AN/A$10.88 per share1.05TCRXTScan Therapeutics$10.32M4.86N/AN/A$2.16 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$19.36M-$1.57N/AN/AN/AN/A-941.15%-368.53%8/13/2026 (Estimated)KROSKeros Therapeutics$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)RNAAvidity Biosciences-$322.30M-$0.97N/AN/AN/A-3,650.39%-44.92%-39.57%8/13/2026 (Estimated)TCRXTScan Therapeutics-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%8/11/2026 (Estimated)Latest TCRX, GLSI, KROS, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026GLSIGreenwich LifeSciences-$0.33N/AN/AN/AN/AN/A8/13/2026Q2 2026RNAAvidity Biosciences-$1.16N/AN/AN/A$0.67 millionN/A8/11/2026Q2 2026TCRXTScan Therapeutics-$0.29N/AN/AN/A$1.88 millionN/A8/5/2026Q2 2026KROSKeros Therapeutics-$1.25N/AN/AN/A$0.81 millionN/A5/14/2026Q1 2026KROSKeros Therapeutics-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 million5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A2.012.01KROSKeros TherapeuticsN/A22.6122.62RNAAvidity BiosciencesN/A9.2011.57TCRXTScan Therapeutics0.346.656.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%KROSKeros Therapeutics71.56%RNAAvidity BiosciencesN/ATCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.47%KROSKeros Therapeutics12.60%RNAAvidity Biosciences3.83%TCRXTScan Therapeutics6.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences314.68 million7.12 millionNot OptionableKROSKeros Therapeutics10019.79 million17.30 millionOptionableRNAAvidity Biosciences19017.11 million149.21 millionOptionableTCRXTScan Therapeutics10065.35 million61.27 millionNot OptionableTCRX, GLSI, KROS, and RNA HeadlinesRecent News About These CompaniesShort Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5%July 30 at 5:59 AM | marketbeat.comTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme MalignanciesJuly 29 at 7:00 AM | globenewswire.comCritical Comparison: Seres Therapeutics (NASDAQ:MCRB) versus TScan Therapeutics (NASDAQ:TCRX)July 20, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by BrokeragesJuly 19, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from AnalystsJuly 19, 2026 | marketbeat.comTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 24, 2026 | globenewswire.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...June 23, 2026 | markets.businessinsider.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationJune 22, 2026 | globenewswire.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3, 2026 | businesswire.comTScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net LossJune 2, 2026 | insidermonkey.comTScan Therapeutics Expands Authorized Shares After Stockholder VoteMay 22, 2026 | tipranks.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%April 18, 2026 | aaii.comATScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceMarch 25, 2026 | insidermonkey.comTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRX, GLSI, KROS, and RNA Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$13.82 +1.03 (+8.01%) As of 12:29 PM Eastern This is a fair market value price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Keros Therapeutics NASDAQ:KROS$10.09 +0.12 (+1.15%) As of 12:29 PM Eastern This is a fair market value price provided by Massive. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Avidity Biosciences NASDAQ:RNA$11.38 +0.20 (+1.79%) As of 12:05 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.TScan Therapeutics NASDAQ:TCRX$0.77 +0.03 (+3.56%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Powering Up: NextEra and Brookfield Build an Off-Grid Empire 2 Unique Space ETFs That Could Upend the Industry DoorDash's Drone Certification Could Reshape Its Delivery Margins Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
